ストックスクリーナーアプリを入手
0.1679
1.24%
-0.0021
アフターアワーズ：
.17
0.0021
+1.25%
Lyra Therapeutics Inc (LYRA) 最新ニュース
William Blair Has Positive Forecast for LYRA FY2024 Earnings - Defense World
HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World
Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Lyra Therapeutics stock plunges to 52-week low of $0.21 By Investing.com - Investing.com South Africa
Lyra Therapeutics stock plunges to 52-week low of $0.21 - Investing.com India
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates - MSN
Lyra Therapeutics Inc (LYRA) Q3 2024 Earnings: Net Loss of $11.9M, Misses EPS and Revenue Estimates - GuruFocus.com
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Lyra Therapeutics Reports Strong Safety Data, Cuts Q3 Losses by 24% as LYR-210 Advances | LYRA Stock News - StockTitan
Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) PT at $4.50 - Defense World
Chronic Rhinosinusitis Market: Driving Rapid Growth with Top - openPR
Lyra Therapeutics Inc (NASDAQ: LYRA) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Lyra Therapeutics completes Phase 3 trial enrollment for CRS treatment By Investing.com - Investing.com Canada
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - The Manila Times
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire
Market Momentum: Lyra Therapeutics Inc (LYRA) Registers a 3.08 Increase, Closing at 0.24 - The Dwinnex
Lyra Therapeutics Inc (LYRA)’s stock price in review: A technical analysis - US Post News
Lyra Therapeutics Inc: Navigating a Turbulent Year, Up -96.61% from 52-Week Low - The InvestChronicle
Lyra Therapeutics stock plunges to 52-week low of $0.24 - Investing.com
Lyra Therapeutics stock plunges to 52-week low of $0.24 By Investing.com - Investing.com UK
What is the investor’s view on Lyra Therapeutics Inc (LYRA)? - US Post News
The time has not yet come to remove your chips from the table: Lyra Therapeutics Inc (LYRA) - SETE News
Where Do Analysts Think The Lyra Therapeutics Inc (NASDAQ: LYRA) Is Going - Stocks Register
Lyra Therapeutics Inc (LYRA) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Lyra Therapeutics to Present Study Results for LYR-210 and - GlobeNewswire
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings - StockTitan
Lyra Therapeutics stock plunges to 52-week low of $0.25 By Investing.com - Investing.com South Africa
Lyra Therapeutics stock plunges to 52-week low of $0.25 - Investing.com
Market Recap: Lyell Immunopharma Inc (LYEL)’s Positive Momentum, Closing at 1.46 - The Dwinnex
XTX Topco Ltd Invests $500,000 in Lindsay Co. (NYSE:LNN) - MarketBeat
Great Point Partners LLC Purchases New Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Defense World
Understanding LXRX’s book value per share for better investment insights - US Post News
All You Need to Know About Tyler Technologies (TYL) Rating Upgrade to Buy - Yahoo Finance
Upward Trajectory: Lexicon Pharmaceuticals Inc (LXRX) Posts a Slidee, Closing at 1.58 - The Dwinnex
Lyell Immunopharma Inc (LYEL)’s stock price in review: A technical analysis - US Post News
Intech Investment Management LLC Buys 1,502 Shares of Tyler Technologies, Inc. (NYSE:TYL) - MarketBeat
Citigroup Acquires Substantial Stake in Syrah Resources - TipRanks
Analysts review Tyler Technologies, Inc.’s rating - Knox Daily
Ratio Examination: Lyra Therapeutics Inc (LYRA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Tyler Technologies, Inc. (NYSE:TYL) Receives $582.31 Average Target Price from Analysts - MarketBeat
GILD: 3 Biotech Stocks to Watch as FDA Approvals Roll In - StockNews.com
There is no doubt that Lyra Therapeutics Inc (LYRA) ticks all the boxes. - SETE News
Renaissance Technologies LLC Acquires 291,000 Shares of LXP Industrial Trust (NYSE:LXP) - Defense World
Acadian Asset Management LLC Makes New Investment in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Are Lyra Therapeutics Inc (LYRA) shares a good deal now? - US Post News
Ratio Revelations: Lyra Therapeutics Inc (LYRA)’s Financial Metrics in the Spotlight - The Dwinnex
The Psychology of Lyra Therapeutics Inc Inc. (LYRA) Price Performance: Understanding Market Sentiment - The InvestChronicle
Taking the lead: Lyra Therapeutics Inc (LYRA) - SETE News
Lyra Therapeutics Inc (LYRA) stock analysis: A simple moving average approach - US Post News
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Given Consensus Rating of “Hold” by Analysts - Defense World
Lyra Therapeutics Inc (LYRA)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
The growth track for Lyra Therapeutics Inc (LYRA) has changed recently - SETE News
Gaining Ground: Lyra Therapeutics Inc (LYRA) Closes Lower at 0.29, Down -4.01 - The Dwinnex
Is it possible to buy Lyra Therapeutics Inc(LYRA) shares at a good price now? - US Post News
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Short Interest Up 18.6% in August - Defense World
A better buy-in window may exist right now for Lyra Therapeutics Inc (LYRA) - SETE News
Was anything negative for Lyra Therapeutics Inc (LYRA) stock last session? - US Post News
Company’s Banking Stock: Dissecting a 5.19% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Despite Recent Gains, Lyra Therapeutics Insiders Are Still Down US$66k - Simply Wall St
Lyra Therapeutics Insiders Still US$66k Away From Original Investment Value - Yahoo Finance
Sinusitis Market to Exhibit Moderate Growth Rate till - openPR
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):